However, he added that until further de-risking of the pharmas obesity portfoliothrough strong efficacy and clean safety data in larger studieshis firm will continue to adopt a more conservative revenue estimate of $865 million by 2032, a far cry from AstraZenecas $5 billion peak projection for its metabolic business
Las inyecciones son ideales para los pacientes que buscan una alternativa ms rentable y que ahorre tiempo a la terapia intravenosa, ya que requieren sesiones ms cortas y menos equipo
While oral [semaglutide] continues to show modest benefits in weight loss and secondary indications relative to injectables, we anticipate next generation assets like orforglipron could start to challenge Novos oral position share in the future, they said
Pappaccogli M, Di Monaco S, Perlo E, et al
For the next 16 years I was told that there is no other logical explanation for symptoms other than MS but never got a firm MS diagnosis
This is what the BPC-157 does